Tag: DOACs
“Transformative” new data advocate early blood-thinning therapy in patients with atrial...
People with atrial fibrillation (AF) who have a stroke could benefit from receiving blood-thinning treatments—known as direct oral anticoagulants (DOACs)—at an earlier stage than...
Early anticoagulation after ischaemic stroke “reasonable” and “unlikely to cause harm”
An international clinical trial presented today at the European Stroke Organisation Conference (ESOC; 24–26 May, Munich, Germany) has demonstrated that—in people with ischaemic stroke...
Alternative timing method for direct oral anticoagulants following ischaemic stroke with...
A new timely practice—known as the “1-2-3-4-day” rule—for the administration of direct oral anticoagulants (DOACs) in patients after acute ischaemic stroke or transient ischaemic...
Analysis of the BRUISE CONTROL 1 and 2 trials shows no...
By Hannah Woolley
In a multivariate analysis including both BRUISE CONTROL 1 and BRUISE CONTROL 2 patients and adjusted for antiplatelet use, there was no...
FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...